A novel Bcl-2 inhibitor, APG-2575, has been granted an Orphan Drug designation (ODD) by the FDA for the treatment of patients with chronic lymphocytic leukemia (CLL), announced Ascentage Pharma in a press release.1
This marks the second ODD for APG-2575, after 1 was granted to the drug in July 2020 for the treatment of Waldenstrm Macroglobulinemia (WM).2
At present, CLL still presents considerable unmet medical needs. APG-2575 is a key drug candidate in Ascentage Pharma's pipeline targeting apoptosis. The APG-2575 received this ODD from the FDA shortly after the first ODD in WM, and this designation will be helpful in enhancing our communication with the FDA and expediting our development of APG-2575 in these rare cancer diseases," said Yifan Zhai, MD, PhD, chief medical officer, Ascentage Pharma, in a statement.1 All the policy support and incentives as a result of this ODD will help us accelerate the global clinical development of APG-2575, which we hope will soon offer additional treatment options for patients with CLL."
In hematologic malignancies, APG-2575 may selectively block Bcl-2 as a way to renew the apoptosis process in cancer cells. The first study of APG-2575 in CLL, as well as in small lymphocytic leukemia (SLL), is currently recruiting 35 patients with relapsed or refractory disease. In the phase 1b dose-escalation study (NCT04215809), patients will receive APG-2575 alone or in combination with other therapeutic agents. The primary end point of the study is dose-limiting toxicity, and the secondary end point is the maximum tolerated dose of APG-2575.
The study will follow a non-randomized 3 + 3 design at a starting dose of 200 mg given on day 1 of a 28-day cycle. The dose will be increased to 400 mg, followed by 600 mg, 800 mg, and 1200 mg.
To be included in the trial, patients must be 18 years or older with a histologically confirmed diagnosis of CLL/SLL, and ECOG performance status of 2 or lower, adequate bone marrow function, and a serum creatinine level of 1.5upper limit of normal. In part 1, patients will be eligible for dose escalation if they have received 3 or fewer prior lines of systemic therapy. Female patients are required to be postmenopausal for 2 years or surgically sterile prior to beginning treatment in the study.
Patients are excluded from this study if they have undergone allogeneic stem cell transplant within 90 days of joining the study, have active graft-versus-host-disease or are in need of immunosuppressive therapy, and/or have Richter's syndrome. The study also excludes patients with certain prior therapies and comorbidities that may interfere with APG-2575 treatment.
Multiple cancer centers in the United States are involved in the phase 1b study of APG-2575 including the Mayo Clinic in Scottsdale Arizona, City of Hope in Duarte, California, Dana-Farber Cancer Institute in Boston, Massachusetts, Novant Health in Charlotte, North Carolina, Grabrail Cancer Center in Canton, Ohio, Cleveland Clinic in Cleveland, Ohio, and Swedish Health in Seattle, Washington.
Outside of the realm CLL/SLL, APG-2575 is being investigated in other hematologic malignancies like WM, AML, and T-cell prolymphocytic leukemia. Studies of APG-2575 in these disease states are currently recruiting patients in centers in the United States, Australia, and China.
References:
1. Ascentage Pharma's Bcl-2 inhibitor apg-2575 granted Orphan Drug designation by the FDA for the treatment of chronic lymphocytic leukemia. News release. Ascentage Pharmaceuticals. September 7, 2020. Accessed September 8, 2020. https://prn.to/2ZiOqFJ
2. Ascentage Pharmas Bcl-2 inhibitor apg-2575 granted Orphan Drug Designation by the FDA for the treatment of waldenstrm macroglobulinemia. News release. Ascentage Pharmaceuticals. July 15, 2020. Accessed September 8, 2020. https://bit.ly/329A5gL
Read more:
FDA Grants Orphan Drug Designation to Novel Bcl-2 inhibitor in CLL - Targeted Oncology
- Making Blood Stem Cells on a Microchip: Academic Minute - December 27th, 2022
- Novel detection of stem cell niche within the stroma of limbus in the rabbit during postnatal development | Scientific Reports - Nature.com - August 14th, 2022
- Why Nebraska's U.S. Airmen have filed a lawsuit refusing the COVID-19 vaccine - KETV Omaha - July 27th, 2022
- Hepatic stellate cells in liver development, regeneration, and cancer - July 11th, 2022
- Fasting triggers stem cell regeneration of damaged, old immune system ... - June 13th, 2022
- Columbus man to be one of first to receive transplant via new OhioHealth program - 10TV - April 19th, 2022
- Grayson authorizes more than $1 million for ongoing and new equine research in 2022 - EQUUS Magazine - March 25th, 2022
- Cancer stem cells in glioblastoma - January 20th, 2022
- First-responder cells after heart attack prompt ... - January 20th, 2022
- New clinical trials from University Hospitals Seidman Cancer Center to begin with human protein following successful on-site approach to producing and... - December 24th, 2021
- Riverside Biologics Health Review: At Home "Stem Cells ... - December 24th, 2021
- China-bound Graduate Focused on Global Goals - University of Mary Washington - December 10th, 2021
- Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia -... - December 10th, 2021
- Fruit Cells, Space Bread, and Cultured Meat Cartridges: Deep Space Food Challenge Announces Phase 1 Winners - The Spoon - October 28th, 2021
- Fungi foray: Wild mushrooms are a key part of food chain - Farm and Dairy - August 5th, 2021
- AgeX Therapeutics Inc. (NYSE:AGE) stock surged in the premarket trading session; heres why - Market Globalist - May 13th, 2021
- University Hospitals treats first cancer patient in Ohio with "game changing" CAR T therapy - News 5 Cleveland - May 13th, 2021
- Weekly line: What the new coronavirus variants mean for vaccines, transmission, and more - The Daily Briefing - January 20th, 2021
- Forge Biologics Announces FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Trial (RESKUE) of FBX-101 Gene Therapy for... - January 9th, 2021
- The Rise of Steve Sarkisian ... And the Decline of the Man Who Got Him Here - Sports Illustrated - January 9th, 2021
- Raleigh man delivers stem cells to patients around the world - WRAL.com - November 28th, 2020
- A real life Superman celebrates 5 years of survival from one of the deadliest cancers - Newswise - November 28th, 2020
- The Museum That Fell From the Sky | History - Air & Space Magazine - November 28th, 2020
- A Detroit Lions VP tries to avoid wasting her daughter from uncommon illness - The Shepherd of the Hills Gazette - November 28th, 2020
- US biotechnology company races to get its COVID-19 therapeutic approved for access, which has previously shown positive results in severely ill... - November 5th, 2020
- STEM CELLS - Regenerative Medicine Institute of Ohio - October 18th, 2020
- Breastfeeding 'even better than previously thought' - The Irish News - The Irish News - June 29th, 2020
- Regenerative Therapy Options for Horses With Osteoarthritis - TheHorse.com - June 12th, 2020
- Why Do Some People Get Sick All the Time, While Others Stay in Freakishly Good Health? - Discover Magazine - June 12th, 2020
- How safe are Ohio summer fun activities amid the coronavirus threat? The Wake Up for Friday, May 29, 2020 - cleveland.com - May 31st, 2020
- Kenneth Wallace Promoted to Full Professor at Clarkson University - Clarkson University News - May 31st, 2020
- ODDS AND ENDS: Melonheads and other offbeat offerings - Toronto Sun - May 31st, 2020
- OHIO researchers win grant to study treatment for possible fatal complications of COVID-19 - Huntington Herald Dispatch - May 8th, 2020
- Coronavirus Today: We're starting to reopen - Los Angeles Times - May 8th, 2020
- COMMENTARY || Pseudoscience and COVID-19we've had enough already - Folio - University of Alberta - May 3rd, 2020
- This Week in Green Tech: STEM Lessons, Solar Power and the Coronavirus, and More - ENGINEERING.com - May 3rd, 2020
- AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure - BioSpace - February 7th, 2020
- Tune in Tonight: Oscar-nominated The Cave debuts on National Geographic - St. Augustine Record - January 25th, 2020
- Best Stem Cell Therapy Treatment in Cincinnati, Ohio ... - November 28th, 2019
- Time to Try Again: Gene-Based Therapy for Neurodegeneration - Alzforum - November 28th, 2019
- NIA Mourns the Loss of Dr. Huber Warner - National Institute on Aging - November 13th, 2019
- Research Roundup: Genomic Dark Matter Mutation and More - BioSpace - October 23rd, 2019
- Stem Cell Treatment Lima | Orthopaedic Institute of Ohio - September 10th, 2019
- Regenerative Therapy in Northeast Ohio | Ohio Therapy Centers - September 9th, 2019
- Stem cell therapy now available in central Ohio! - May 30th, 2019
- Stem Cell Therapy Clinic in Cleveland, Ohio - March 26th, 2019
- Massages & Treatments | Day Spa on Lake Erie in Ohio | The ... - March 10th, 2019
- *NEW* Regenerative Stem Cell Therapy | Ohio Therapy Centers - December 7th, 2018
- Stem Cell Therapy | Ohio Stem Cell - November 5th, 2018
- Ohio Stem Cell Treatment Center of Cleveland (Beachwood ... - November 3rd, 2018
- Conjoined twins - Wikipedia - September 20th, 2018
- Government website steers patients to unproven medical treatments - MyAJC - September 2nd, 2017
- Modern Health & Wellness of Lima institutes regenerative stem cell therapy - Lima Ohio - September 2nd, 2017
- Salk faces 'daunting' need for money despite big success with ... - The San Diego Union-Tribune - August 26th, 2017
- 'Nanotransfection' Turns Animal Skin into Blood Vessels and Brain ... - Medical Device and Diagnostics Industry - August 26th, 2017
- This Chip Uses Electricity to Reprogram Cells for Healing - Singularity Hub - August 25th, 2017
- This year's freshman class at Misericordia University is third largest in school history - The Dallas Post - August 25th, 2017
- Nanochip Could Heal Injuries or Regrow Organs with One Touch - NewsFactor Network - August 18th, 2017
- Wild new microchip tech could grow brain cells on your skin - CNET - August 8th, 2017
- Researchers explore possible alternative to knee replacement - Scope (blog) - August 5th, 2017
- Jackson Twp.'s Emmie Wanzer loves her new wheelchair swing provided by Wishes Can Happen Wanzer - Canton Repository - July 4th, 2017
- Scientists Discover That Fasting Triggers Stem Cell ... - November 23rd, 2016
- Stem-Cells | The Institute for Applied & Professional Ethics - November 18th, 2016
- Stem Cell Transplant Program - Cleveland, Ohio - October 17th, 2016
- Update: Ohio Stem Cell Study Recruiting People with MS ... - October 17th, 2016
- National Center For Regenerative Medicine - October 17th, 2016
- Stem-cell niche - Wikipedia, the free encyclopedia - October 19th, 2015
- Alex Potoczak of Ohio Praises Umbilical Stem Cell Research ... - July 2nd, 2015
- Dr. Foglietti | Ohio Stem Cell Treatment Center of Cleveland - April 27th, 2015
- Taubman Institute Receives $3 Million Wexner Gift to Support Emerging Physician-Researchers - April 3rd, 2015
- Morgan's Fund Launches Necrotizing Enterocolitis (NEC) Podcast Series: Premiere Features Dr. Gail Besner - March 24th, 2015
- Ohio Stem Cell Knee Arthritis Treatment-Regenexx - February 23rd, 2015
- We Were Promised Space Lasers: The State of the Union's Biggest Fibs - January 21st, 2015
- We Were Promised Space Lasers: State of the Union's Biggest Fibs - January 20th, 2015
- We Were Promised Space Lasers: The State of the Union's Big Fibs - January 17th, 2015
- 'Unprecedented': Drug May Help Heal Damaged Spines - December 4th, 2014
- New DNA discovery could lead to chromosome therapies in the future - November 19th, 2014
- Tiny Stomachs Grown in the Lab - October 31st, 2014
- Stem Cells Used to Grow Mini-Stomachs Seeking Treatments - October 30th, 2014
- Scientists build 'mini-stomachs' in lab - October 30th, 2014